GC Biopharma and Hanmi Pharmaceutical announced on July 1st that they have submitted Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase 1/2 clinical trials of ‘(LA-GLA),’ a treatment for Fabry disease that they are co-developing.

LA-GLA is an innovative new drug to treat Fabry disease. GC Biopharma and Hanmi Pharmaceutical are co-developing it as the 'world's first once-monthly subcutaneous dosing.'

Fabry disease is a rare disease inherited in an X-chromosome and is a type of lysosomal storage disease (LSD). It occurs when 'alpha-galactosidase A,' the enzyme needed to break down the glycolipid in the lysosome. It is a progressive, rare,